Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 6, 2012, Pages

  Lebastchi, Jasmin ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BIOLOGICAL MARKER; C PEPTIDE; CD20 ANTIBODY; CD3 ANTIBODY; CXCL1 CHEMOKINE; EXENDIN 4; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA DR4 ANTIGEN; INSULIN ANTIBODY; INSULINOMA ASSOCIATED ANTIGEN 2; INTERLEUKIN 10; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PANCREAS ISLET CELL ANTIBODY; PREPROINSULIN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; RITUXIMAB; TEPLIZUMAB; TETRAMER; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; ZINC TRANSPORTER; AUTOANTIBODY;

ANTIGEN ANTIBODY REACTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL DESTRUCTION; CELL PROLIFERATION ASSAY; CELLULAR IMMUNITY; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; IMMUNOSTIMULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BLOOD; CELL PROLIFERATION; FLUORESCENCE IMAGING; IMMUNOLOGY; METABOLISM; ORGAN SIZE; PANCREAS ISLET; PATHOLOGY; REVIEW; T LYMPHOCYTE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; C-PEPTIDE; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MAGNETIC RESONANCE IMAGING; OPTICAL IMAGING; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES;

EID: 84879831638     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007708     Document Type: Article

References (53)

1. Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM, Herold KC. 2011. Detection of beta cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci 108: 19018-19023.
2. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, PeakmanM. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113: 451-463.
3. Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, Vives-Pi M, Powrie J, Tree T, Marchetti P, et al. 2011. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes 60: 2112-2119.
4. Atkinson MA, Maclaren NK. 1994. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428-1436.
5. Berney T, Mamin A, James Shapiro AM, Ritz-Laser B, Brulhart MC, Toso C, Demuylder-Mischler S, Armanet M, Baertschiger R, Wojtusciszyn A, et al. 2006. Detection of insulin mRNA in the peripheral blood after human islet transplantion predicts deterioration of metabolic control. Am J Transplant 6: 1704-1711.
6. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, et al. 1988. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318: 663-670.
7. Brom M, Andralojc K, Oyen WJ, Boerman OC, Gotthardt M. 2010. Development of radiotracers for the determination of the β-cell mass in vivo. Curr Pharm Des 16: 1561-1567.
8. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JP. 2001. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 166: 5265-5270.
9. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC. 2006. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54: 3612-3622.
10. Cernea S, Herold KC. 2010. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol 134: 121-129.
11. Coppieters KT, Roep BO, von Herrath MG. 2011. β cells under attack: Toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol 33: 1-7.
12. Dosch H, Cheung RK, Karges W, Pietropaolo M, Becker DJ. 1999. Persistent T cell anergy in human type 1 diabetes. J Immunol 163: 6933-6940.
13. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. 1992. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405.
14. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, Mathis D, Weissleder R. 2011. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 121: 442-445.
15. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, Hirsch J, PrinceM, Maffei A, Mann JJ, et al. 2009. 11C-Dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 50: 382-389.
16. Greenbaum C, Seidel K, Pihoker C. 2004. The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. Diabetes Care 27: 1202-1204.
17. Greenbaum C, et al. 2012. Biphasic fall in C-peptide over first two years from diagnosis: Composite TrilaNet data. Diabetes (in press).
18. Hampe CS, Wallen AR, Schlosser M, Ziegler M, Sweet IR. 2005. Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic β cell mass. Exp Clin Endocrinol Diabetes 113: 381-387.
19. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. 2003. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 52: 1137-1142.
20. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698.
21. Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, et al. 2009. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 58: 2588-2595.
22. Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM. 2011. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 187: 1998-2005.
23. Huang H, Benoist C, Mathis D. 2010. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci 107: 4658-4663.
24. Karvonen M, Tuomilehto J, Libman I, LaPorte R. 1993. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group. Diabetologia 36: 883-892.
25. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, HaleG, Gorus F, Goldman M, Walter M, Candon S, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608.
26. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS. 2003. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 88: 103-108.
27. Maffei A, Liu Z, Witkowski P, Moschella F, Del Pozzo G, Liu E, Herold K, Winchester RJ, Hardy MA, Harris PE. 2004. Identification of tissue-restricted transcripts in human islets. Endocrinology 145: 4513-4521.
28. Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, Bjoerndalen H, de Beaufort C, Chiarelli F, Danne T, et al. 2009. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32: 1384-1390.
29. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G. 2009. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32: 2269-2274.
30. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, ParikkaV, Katajamaa M, Hekkala A, Mattila I, Keskinen P, et al. 2008. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205: 2975-2984.
31. Ouyang Q, Standifer NE, Qin H, Gottlieb P, Verchere CB, Nepom GT, Tan R, Panagiotopoulos C. 2006. Recognition of HLA class I-restricted β-cell epitopes in type 1 diabetes. Diabetes 55: 3068-3074.
32. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, et al. 2004. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 53: 250-264.
33. Pattou F, Kerr-Conte J, Wild D. 2010. GLP-1-receptor scanning for imaging of human β cells transplanted in muscle. N Engl J Med 363: 1289-1290.
34. Pflueger M, Seppanen-Laakso T, Suortti T, Hyotylainen T, Achenbach P, Bonifacio E, Oresic M, Ziegler AG. 2011. Age-and islet autoimmunity-associated differences in amino acid and lipid metabolites in children at risk for type 1 diabetes. Diabetes 60: 2740-2747.
35. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, Keymeulen B, Pipeleers D, Drijfhout JW, Roep BO. 2005. Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes. Proc Natl Acad Sci 102: 18425-18430.
36. Rakyan VK, Down TA, Balding DJ, Beck S. 2011. Epigenome-wide association studies for common human diseases. Nat Rev Genet 12: 529-541.
37. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-WorrellB, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, et al. 2006. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: Results of a blinded controlled study. Diabetes 55: 2588-2594.
38. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. 2006. Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes. Diabetes 55: 3238-3245.
39. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr., Bode B, Aronoff S, Holland C, Carlin D, et al. 2011. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378: 487-497.
40. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, ChaseHP, White NH, Buckingham B, Herold KC, et al. 2006. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29: 643-649.
41. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, MathesonD, Skyler JS. 2008. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 31: 2188-2192.
42. Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, Kilbourn M, GolandR, Leibel R, Mann JJ, et al. 2006. Longitudinal noninvasive PET-based β cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116: 1506-1513.
43. Standifer NE, Ouyang Q, Panagiotopoulos C, Verchere CB, Tan R, GreenbaumCJ, Pihoker C, Nepom GT. 2006. Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes 55: 3061-3067.
44. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. 2004. Insulin secretion in type 1 diabetes. Diabetes 53: 426-433.
45. Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, RodgerNW, von Graffenried B, Wolfe BM. 1984. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362-1367.
46. Takahashi K, Ohara M, Sasai T, Homma H, Nagasawa K, Takahashi T, Yamashina M, Ishii M, Fujiwara F, Kajiwara T, et al. 2011. Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity. Diabetes Metab Res Rev 27: 830-833.
47. Toso C, Vallee JP, Morel P, Ris F, Demuylder-Mischler S, Lepetit-Coiffe M, Marangon N, Saudek F, James Shapiro AM, Bosco D, et al. 2008. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant 8: 701-706.
48. Tsai EB, Sherry NA, Palmer JP, Herold KC. 2006. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49: 261-270.
49. Ueberberg S, Meier JJ, Waengler C, Schechinger W, Dietrich JW, Tannapfel A, Schmitz I, Schirrmacher R, Koller M, Klein HH, et al. 2009. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic β-or α-cells in vivo. Diabetes 58: 2324-2334.
50. + T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59: 1721-1730.
51. Wang P, Medarova Z, Moore A. 2011. Molecular imaging: A promising tool to monitor islet transplantation. J Transplant 2011: 202915.
52. Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, Pugliese A, Krischer J, Eisenbarth GS. 2011. Rituximab selectively suppresses specific islet antibodies. Diabetes 60: 2560-2565.
53. Zak KP, Popova VV, Mel'nichenko SV, Tron'ko EN, Man'kovskii BN. 2010. The level of circulating cytokines and chemokines in the preclinical and early clinical stages of type IA diabetes mellitus development. Ter Arkh 82: 10-15.